These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2007852)

  • 1. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain.
    Tao MH; Canfield SM; Morrison SL
    J Exp Med; 1991 Apr; 173(4):1025-8. PubMed ID: 2007852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement.
    Sensel MG; Kane LM; Morrison SL
    Mol Immunol; 1997 Oct; 34(14):1019-29. PubMed ID: 9488053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement.
    Xu Y; Oomen R; Klein MH
    J Biol Chem; 1994 Feb; 269(5):3469-74. PubMed ID: 8106388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
    Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
    Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
    Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
    Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CH2 Domain of Mouse IgG3 Governs Antibody Oligomerization, Increases Functional Affinity to Multivalent Antigens and Enhances Hemagglutination.
    Klaus T; Bereta J
    Front Immunol; 2018; 9():1096. PubMed ID: 29875771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
    Zuckier LS; Chang CJ; Scharff MD; Morrison SL
    Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge.
    Norderhaug L; Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
    Eur J Immunol; 1991 Oct; 21(10):2379-84. PubMed ID: 1915551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.
    Canfield SM; Morrison SL
    J Exp Med; 1991 Jun; 173(6):1483-91. PubMed ID: 1827828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping rheumatoid factor binding sites using genetically engineered, chimeric IgG antibodies.
    Bonagura VR; Artandi SE; Agostino N; Tao MH; Morrison SL
    DNA Cell Biol; 1992 Apr; 11(3):245-52. PubMed ID: 1567557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
    Bindon CI; Hale G; Brüggemann M; Waldmann H
    J Exp Med; 1988 Jul; 168(1):127-42. PubMed ID: 3260935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.
    Tao MH; Smith RI; Morrison SL
    J Exp Med; 1993 Aug; 178(2):661-7. PubMed ID: 8340761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of human complement by mouse and mouse/human chimeric monoclonal antibodies.
    Seino J; Eveleigh P; Warnaar S; van Haarlem LJ; van Es LA; Daha MR
    Clin Exp Immunol; 1993 Nov; 94(2):291-6. PubMed ID: 8222320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of complement by an IgG molecule without a genetic hinge.
    Brekke OH; Michaelsen TE; Sandin R; Sandlie I
    Nature; 1993 Jun; 363(6430):628-30. PubMed ID: 8510754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staphylococcal protein A and human IgG subclasses and allotypes.
    Van Loghem E; Frangione B; Recht B; Franklin EC
    Scand J Immunol; 1982 Mar; 15(3):275-8. PubMed ID: 7089488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural motifs involved in human IgG antibody effector functions.
    Greenwood J; Clark M; Waldmann H
    Eur J Immunol; 1993 May; 23(5):1098-104. PubMed ID: 8477804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin.
    Shiga Y; Murata D; Sugimoto A; Oshima Y; Tada M; Ishii-Watabe A; Imai K; Tomii K; Takeuchi T; Kagaya S; Sato A
    Mol Pharm; 2017 Sep; 14(9):3025-3035. PubMed ID: 28763236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
    Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
    J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies.
    Chappel MS; Isenman DE; Everett M; Xu YY; Dorrington KJ; Klein MH
    Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9036-40. PubMed ID: 1833770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.
    Wright A; Morrison SL
    J Exp Med; 1994 Sep; 180(3):1087-96. PubMed ID: 8064227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.